Molecure S.A. (WSE:MOC)

Market Cap	117.44M -28.8%
Revenue (ttm)	6.52M +123.3%
Net Income	-15.69M
EPS	-0.76
Shares Out	20.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,518
Open	5.28
Previous Close	5.48
Day's Range	5.26 - 5.79
52-Week Range	4.98 - 9.06
Beta	1.03
Analysts	Strong Buy
Price Target	12.45 (+118.42%)
Earnings Date	May 18, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 71
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MOC

Financial Performance

In 2025, Molecure's revenue was 6.52 million, an increase of 123.34% compared to the previous year's 2.92 million. Losses were -15.69 million, -49.86% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for MOC stock is "Strong Buy." The 12-month stock price target is zł 12.45, which is an increase of 118.42% from the latest price.

Price Target

zł 12.45

(118.42% upside)

Analyst Consensus: Strong Buy